| Over a week ago | ||||
Virtual Meeting with CEO… Virtual Meeting with CEO Murphy-Chutorian and CMO Rosenberg to be held on May 11 hosted by Lake Street. | ||||
B. Riley analyst Marc… B. Riley analyst Marc Wiesenberger lowered the firm's price target on Semler Scientific to $60 from $70 and keeps a Buy rating on the shares. The company reported Q1 results below expectations as a result of omicron impacts early in the quarter and elevated investments for upcoming opportunities, Wiesenberger tells investors in a research note. It has become clear that 2022 is an investment year for Semler, "solidifying its infrastructure to not only grow QuantaFlo on the heals of important data from a recently released peer-reviewed study, but also its two externally sourced new products," writes the analyst. | ||||
Virtual Meeting with CEO… Virtual Meeting with CEO Murphy-Chutorian and CMO Rosenberg to be held on May 11 hosted by Lake Street. | ||||
| Over a month ago | ||||
B. Riley analyst Marc… B. Riley analyst Marc Wiesenberger views Semler Scientific's buyback announcement as an important signal to the market, saying it reflects management's confidence in the company's current financial position and future outlook for the business, despite recent volatility in results. The analyst believes the buyback is the most productive use of cash in the near term. The news "should put a floor under shares here in the mid-$40 range," Wiesenberger tells investors in a research note. He reiterates a Buy rating on Semler with a $70 price target. | ||||
Semler Scientific… Semler Scientific announced that its board of directors has authorized a $20M stock repurchase program. The repurchase program has no expiration date, does not require the purchase of any minimum number of shares and may be suspended, modified or discontinued at any time without prior notice. | ||||
B. Riley analyst Marc… B. Riley analyst Marc Wiesenberger lowered the firm's price target on Semler Scientific to $70 from $145 and keeps a Buy rating on the shares following the Q4 results. The analyst says that while near-term volatility around variable-fee revenue may increase as in-home evaluations are reduced, the oscillations should occur around a sustained upward trajectory. Semler's business trajectory cannot sustain levels seen in late 2020 and early 2021, but secular trends around preventive care/diagnostics and in-home care remain unchanged, Wiesenberger tells investors in a research note. | |
Lake Street analyst… Lake Street analyst Brooks O'Neil lowered the firm's price target on Semler Scientific to $100 from $175 and keeps a Buy rating on the shares after the company reported Q4 results below his forecast and consensus in an apparent reflection of a change of order pattern from a large fee-per-test customer. Since it seems plausible this pattern will repeat in 2022, O'Neil is lowering his forecast for 2022 in an effort to reflect new expectations and he acknowledges this "could change investor attitudes related to SMLR shares, at least temporarily." | |
Semler Scientific… Semler Scientific announced a study was published on-line as a pre-proof in the peer-reviewed Journal of Vascular Surgery with data collected using QuantaFlo under real-world conditions. The article is, "The Nevada Peripheral Artery Disease Screening Effort in a Medicare Advantage Population and Subsequent Mortality and Major Adverse Cardiovascular Event Riski." The study analyzed screening tests using QuantaFlo for undetected and asymptomatic peripheral arterial disease in a Medicare Advantage population with three-year follow up. In this study, 13,971 patients were tested and 31.6% had a positive result for PAD. The large metropolitan area was characterized by concentrations of atherosclerotic risk factors along with a more vulnerable socio-economic risk profile. The risk associated with detecting PAD was substantial with a 60-70% increased risk of all-cause mortality or morbidity at one year and a 40-50% increased risk of all-cause mortality or morbidity at three years. The association of risk at three years was not modified following multivariable adjustment. The study's take home message: "A positive screening result of previously undetected lower extremity PAD was independently associated with short-term and long-term increased risks for mortality and major adverse cardiovascular events in individuals aged 65 years and older living in a large, metropolitan area." | |
Reports Q4 revenue… Reports Q4 revenue $11.5M, consensus $13.05M. "It is our belief that annual adoption of our QuantaFlo product continues to expand due to the clinical benefits of earlier recognition of vascular disease. In 2021 as compared to 2020, we experienced a timing shift in the home-testing market, which led to first half revenue being greater than the second half of 2021," said Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific. " |
| Over a quarter ago | ||||
Virtual Meeting to be… Virtual Meeting to be held on January 18 hosted by B. Riley. | ||||
